InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Phase 3 Data on Fibromyalgia Drug at EULAR 2025
Tonix Pharmaceuticals (NASDAQ: TNXP) presented new data at the 2025 Annual European Congress of Rheumatology (EULAR) in Barcelona supporting TNX-102 SL, its sublingual cyclobenzaprine formulation for fibromyalgia. The poster highlighted results from the RESILIENT Phase 3 trial showing statistically significant, sustained pain reduction over 14 weeks, along with improved sleep and favorable tolerability. Designed to bypass first-pass liver metabolism, TNX-102 SL achieved higher nighttime cyclobenzaprine…